Fate Therapeutics to Participate in Leerink Partners 2026 Global Healthcare Conference
Rhea-AI Summary
Fate Therapeutics (NASDAQ: FATE) announced management will participate in the Leerink Partners 2026 Global Healthcare Conference on Monday, March 9, 2026 in Miami, Florida.
Management will join a fireside chat at 9:20 AM ET, host investor meetings, and provide a live webcast with an archived replay available for 90 days.
Positive
- None.
Negative
- None.
News Market Reaction – FATE
On the day this news was published, FATE gained 5.84%, reflecting a notable positive market reaction. Argus tracked a peak move of +6.5% during that session. Argus tracked a trough of -3.6% from its starting point during tracking. Our momentum scanner triggered 10 alerts that day, indicating notable trading interest and price volatility. This price movement added approximately $9M to the company's valuation, bringing the market cap to $172.07M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
Peers show mixed moves: CRBP -1.53%, TARA -5.09% vs. EQ +7.87%, FBRX +2.78%, KALA +2.11%, while FATE is up 1.35%. Combined with no peers in the momentum scanner, this suggests stock-specific trading rather than a coordinated sector move.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Feb 26 | Earnings and update | Positive | +5.4% | Q4 and 2025 results with strong cash and reduced operating expenses. |
| Feb 03 | Inducement awards | Neutral | -0.9% | New-hire stock options and RSUs under Nasdaq inducement rule. |
| Jan 05 | Inducement awards | Neutral | +0.0% | Equity awards to new hires via options and RSUs for recruitment. |
| Dec 08 | Clinical data update | Positive | -0.9% | Updated Phase 1 FT819 data and preclinical advances for FT836/FT839. |
| Nov 25 | Conference presentation | Neutral | -1.9% | Participation in Piper Sandler healthcare conference with fireside chat. |
Recent news, including earnings and clinical data, has more often seen price moves that align modestly with the news tone, with one notable divergence on positive clinical data.
Over the last few months, Fate Therapeutics has reported Q4 and full-year 2025 results, highlighted by $205.1 million in cash, projected runway through year-end 2027, and lower operating expenses, which saw a 5.41% positive price reaction. Routine inducement equity awards in January and February 2026 had minimal impact. In December 2025, encouraging Phase 1 FT819 data and preclinical advances for FT836/FT839 coincided with a small negative move, while a November 2025 conference presentation also saw a modest decline. Today’s conference participation fits this pattern of neutral corporate visibility events.
Market Pulse Summary
The stock moved +5.8% in the session following this news. A strong positive reaction aligns with Fate’s position above its 200-day MA of $1.17 and within the upper half of its 52-week range, with shares at $1.50. Historically, even solid clinical updates produced only modest moves, and one key data release saw a -0.93% divergence. Investors have also seen frequent conference appearances as neutral. Any extended strength could eventually confront prior dilution-free capital needs and insider sell-to-cover activity as potential overhangs.
Key Terms
induced pluripotent stem cell medical
cellular immunotherapies medical
webcast technical
AI-generated analysis. Not financial advice.
SAN DIEGO, March 03, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases, today announced that management will participate in a fireside chat and host investor meetings at the Leerink Partners 2026 Global Healthcare Conference on Monday, March 9, 2026 in Miami, Florida.
Management will participate in a fireside chat at 9:20 AM ET on Monday, March 9. A live webcast of the fireside chat can be accessed under “Events & Presentations” in the Investors section of the Company’s website at www.fatetherapeutics.com. An archived replay of the webcast will be available for 90 days on the Company’s website following the event.
About Fate Therapeutics, Inc.
Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases. Using its proprietary iPSC product platform, the Company has established a leadership position in creating multiplexed-engineered master iPSC lines and in the manufacture and clinical development of off-the-shelf, iPSC-derived cell products. The Company’s pipeline includes iPSC-derived T-cell and natural killer (NK) cell product candidates, which are selectively designed, incorporate novel synthetic controls of cell function, and are intended to deliver multiple therapeutic mechanisms to patients. Fate Therapeutics is headquartered in San Diego, CA. For more information, please visit www.fatetherapeutics.com.
Contact:
Ryan Douglas
Fate Therapeutics, Inc.
IR@fatetherapeutics.com
